{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:58:37Z","timestamp":1786089517006,"version":"3.56.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T00:00:00Z","timestamp":1378944000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1003226","type":"journal-article","created":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T21:23:58Z","timestamp":1379021038000},"page":"e1003226","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":78,"title":["Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways"],"prefix":"10.1371","volume":"9","author":[{"given":"Jing","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Karhinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Szwajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwan","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"Wennerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tero","family":"Aittokallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,9,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrd3405","article-title":"The productivity crisis in pharmaceutical R&D","volume":"10","author":"F Pammolli","year":"2011","journal-title":"Nature Reviews Drug Discovery"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrclinonc.2011.34","article-title":"High drug attrition rates\u2014where are we going wrong?","volume":"8","author":"L Hutchinson","year":"2011","journal-title":"Nature Reviews Clinical Oncology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"AL Hopkins","year":"2008","journal-title":"Nat Chem Biol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd2683","article-title":"Mechanisms of drug combinations: interaction and network perspectives","volume":"8","author":"J Jia","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"B Al-Lazikani","year":"2012","journal-title":"Nat Biotechnol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMcibr072593","article-title":"Rational design of cancer-drug combinations","volume":"357","author":"S Ramaswamy","year":"2007","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nbt.1549","article-title":"Synergistic drug combinations tend to improve therapeutically relevant selectivity","volume":"27","author":"J Leh\u00e1r","year":"2009","journal-title":"Nat Biotechnol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrd2089","article-title":"Strategies for optimizing combinations of molecularly targeted anticancer agents","volume":"5","author":"JE Dancey","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev-pharmtox-010611-134630","article-title":"Novel computational approaches to polypharmacology as a means to define responses to individual drugs","volume":"52","author":"L Xie","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrg2841","article-title":"Advances in understanding cancer genomes through second-generation sequencing","volume":"11","author":"M Meyerson","year":"2010","journal-title":"Nat Rev Genet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.cell.2011.03.001","article-title":"Principles and strategies for developing network models in cancer","volume":"144","author":"D Pe'er","year":"2011","journal-title":"Cell"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"WG Kaelin Jr","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMe0903044","article-title":"Synthetic lethality\u2013a new direction in cancer-drug development","volume":"361","author":"JD Iglehart","year":"2009","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cell.2011.03.020","article-title":"Genetic Interactions in Cancer Progression and Treatment","volume":"145","author":"A Ashworth","year":"2011","journal-title":"Cell"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nature05697","article-title":"Synthetic lethal screen identification of chemosensitizer loci in cancer cells","volume":"446","author":"AW Whitehurst","year":"2007","journal-title":"Nature"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2009.05.006","article-title":"A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene","volume":"137","author":"J Luo","year":"2009","journal-title":"Cell"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"DA Barbie","year":"2009","journal-title":"Nature"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.gde.2010.10.009","article-title":"Searching for synthetic lethality in cancer","volume":"21","author":"R Brough","year":"2011","journal-title":"Curr Opin Genet Dev"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1471-2105-13-S7-S7","article-title":"Exploring drug combinations in genetic interaction network","volume":"13","author":"Y-Y Wang","year":"2012","journal-title":"BMC Bioinformatics"},{"key":"ref20","article-title":"Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles","author":"J Tang","year":"2013","journal-title":"Curr Pharm Des"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/msb.2008.60","article-title":"Finding multiple target optimal intervention in disease-related molecular network","volume":"4","author":"K Yang","year":"2008","journal-title":"Mol Syst Biol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/msb.2011.35","article-title":"Predicting selective drug targets in cancer through metabolic networks","volume":"7","author":"O Folger","year":"2011","journal-title":"Mol Syst Biol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e1002267","DOI":"10.1371\/journal.pcbi.1002267","article-title":"Dynamical and structural analysis of a T cell survival network identifies novel candidate therapeutic targets for large granular lymphocyte leukemia","volume":"7","author":"A Saadatpour","year":"2011","journal-title":"PLoS Comput Biol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1158\/1535-7163.MCT-06-0497","article-title":"Prediction of drug combination chemosensitivity in human bladder cancer","volume":"6","author":"DM Havaleshko","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/msb.2008.53","article-title":"Models from experiments: combinatorial drug perturbations of cancer cells","volume":"4","author":"S Nelander","year":"2008","journal-title":"Mol Syst Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejps.2011.10.026","article-title":"Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2\/3 network","volume":"46","author":"G Lebedeva","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1158\/0008-5472.CAN-10-0460","article-title":"Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis","volume":"70","author":"S Iadevaia","year":"2010","journal-title":"Cancer Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nchembio.503","article-title":"A mammalian functional-genetic approach to characterizing cancer therapeutics","volume":"7","author":"H Jiang","year":"2011","journal-title":"Nat Chem Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"E771","DOI":"10.1073\/pnas.1106149108","article-title":"Modulatory profiling identifies mechanisms of small molecule-induced cell death","volume":"108","author":"AJ Wolpaw","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref30","first-page":"351","article-title":"A kinase inhibition map approach for tumor sensitivity prediction and combination therapy design for targeted drugs","author":"R Pal","year":"2012","journal-title":"Pac Symp Biocomput"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"J Barretina","year":"2012","journal-title":"Nature"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","article-title":"ChEMBL: a large-scale bioactivity database for drug discovery","volume":"40","author":"A Gaulton","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrc2787","article-title":"Targeting the cancer kinome through polypharmacology","volume":"10","author":"ZA Knight","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"ref34","first-page":"279","article-title":"Floating search methods for feature selection with nonmonotonic criterion functions","volume":"2","author":"P Pudil","year":"1994","journal-title":"Pattern Recognit"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1073\/pnas.0712255105","article-title":"Defining genetic interaction","volume":"105","author":"R Mani","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/nmeth.1534","article-title":"Quantitative analysis of fitness and genetic interactions in yeast on a genome scale","volume":"7","author":"A Baryshnikova","year":"2010","journal-title":"Nat Methods"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nmeth.2436","article-title":"Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping","volume":"10","author":"C Laufer","year":"2013","journal-title":"Nat Methods"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/ng1755","article-title":"Functional classification of drugs by properties of their pairwise interactions","volume":"38","author":"P Yeh","year":"2006","journal-title":"Nat Genet"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/msb.2011.71","article-title":"Systematic exploration of synergistic drug pairs","volume":"7","author":"M Cokol","year":"2011","journal-title":"Mol Syst Biol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"MW Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"MI Davis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/0008-5472.CAN-12-1906","article-title":"Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening","volume":"73","author":"JW Tyner","year":"2013","journal-title":"Cancer Res"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"D1128","DOI":"10.1093\/nar\/gkr797","article-title":"Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery","volume":"40","author":"F Zhu","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"D400","DOI":"10.1093\/nar\/gkr1132","article-title":"PubChem's BioAssay Database","volume":"40","author":"Y Wang","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nmeth.1351","article-title":"Statistical methods for analysis of high-throughput RNA interference screens","volume":"6","author":"A Birmingham","year":"2009","journal-title":"Nat Methods"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/ni0809-799","article-title":"RNAi screening: tips and techniques","volume":"10","author":"S Sharma","year":"2009","journal-title":"Nat Immunol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/nbt.2021","article-title":"Interrogating the kinome","volume":"29","author":"C Zhang","year":"2011","journal-title":"Nature Biotechnology"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e18261","DOI":"10.1371\/journal.pone.0018261","article-title":"RNAi-Based Screening Identifies Kinases Interfering with Dioxin-Mediated Up-Regulation of CYP1A1 Activity","volume":"6","author":"D Gilot","year":"2011","journal-title":"PLoS ONE"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/gb-2006-7-7-r66","article-title":"Analysis of cell-based RNAi screens","volume":"7","author":"M Boutros","year":"2006","journal-title":"Genome Biol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.1002\/ijc.27813","article-title":"Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from na\u00efve Asian NSCLC patients","volume":"132","author":"M Yang","year":"2013","journal-title":"Int J Cancer"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1747-0285.2011.01239.x","article-title":"Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen","volume":"78","author":"S Zhang","year":"2011","journal-title":"Chem Biol Drug Des"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1091\/mbc.11.11.3835","article-title":"Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression","volume":"11","author":"A Dey","year":"2000","journal-title":"Mol Biol Cell"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.onc.1209843","article-title":"Oncogenic tyrosine kinase NPM\/ALK induces activation of the MEK\/ERK signaling pathway independently of c-Raf","volume":"26","author":"M Marzec","year":"2007","journal-title":"Oncogene"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/WNR.0b013e3283186bf8","article-title":"Expression of a chimeric CSF1R-LTK mediates ligand-dependent neurite outgrowth","volume":"19","author":"S Yamada","year":"2008","journal-title":"Neuroreport"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.bcp.2011.11.005","article-title":"Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors","volume":"83","author":"L Xie","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1038\/sj.onc.1209494","article-title":"AURKA is one of the downstream targets of MAPK1\/ERK2 in pancreatic cancer","volume":"25","author":"T Furukawa","year":"2006","journal-title":"Oncogene"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/bjc.2012.8","article-title":"The MEK1\/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models","volume":"106","author":"SV Holt","year":"2012","journal-title":"Br J Cancer"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/msb.2009.98","article-title":"A side effect resource to capture phenotypic effects of drugs","volume":"6","author":"M Kuhn","year":"2010","journal-title":"Mol Syst Biol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"D1060","DOI":"10.1093\/nar\/gkq1037","article-title":"PROMISCUOUS: a database for network-based drug-repositioning","volume":"39","author":"J Von Eichborn","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1049\/iet-syb.2008.0166","article-title":"Detecting drug targets with minimum side effects in metabolic networks","volume":"3","author":"Z Li","year":"2009","journal-title":"IET Syst Biol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"e1002323","DOI":"10.1371\/journal.pcbi.1002323","article-title":"Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data","volume":"7","author":"X-M Zhao","year":"2011","journal-title":"PLoS Comput Biol"}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1003226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T04:38:00Z","timestamp":1588999080000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1003226"}},"subtitle":[],"editor":[{"given":"Frederick P.","family":"Roth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,9,12]]},"references-count":61,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,9,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1003226","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,12]]}}}